Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Abstract: This invention relates to epitope binding agents that specifically bind to tau and methods of use thereof. The disclosure provides immunoassays, kits, and pharmaceutical compositions which include an epitope binding agent that specifically bind to tau. The disclosure provides methods of reducing the spread of tau aggregates and methods of reducing a tauopathy-related pathology.

Abstract: The present invention provides anti-tau constructs. Anti-tau constructs of the invention are polynucleotide sequences encoding a polypeptide comprising at least one tau binding moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by anti-tau constructs, vectors comprising anti-tau constructs, and isolated cells comprising said vectors.

Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Abstract: The present disclosure encompasses anti-TREM-2 antibodies that promote TREM-2 activation and methods of using the anti-TREM-2 agonist antibodies therapeutically.

Abstract: The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.

Abstract: The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.

Abstract: The present invention provides anti-tau constructs. Anti-tau constructs of the invention are polynucleotide sequences encoding a polypeptide comprising at least one tau binding moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by anti-tau constructs, vectors comprising anti-tau constructs, and isolated cells comprising said vectors.

Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Abstract: This invention relates to antibodies to tau and methods of use thereof.

Abstract: The present invention provides anti-tau constructs. Anti-tau constructs of the invention are polynucleotide sequences encoding a polypeptide comprising at least one tau binding moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by anti-tau constructs, vectors comprising anti-tau constructs, and isolated cells comprising said vectors.

Abstract: This invention relates to antibodies to tau and methods of use thereof.

Abstract: The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.

Abstract: The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of A? plaque associated symptoms or for decreasing amyloid plaque loads. The method comprises administering an effective amount of an anti-ApoE antibody to a living mammalian biosystem such as to a human.

Abstract: The present invention relates to methods of detecting, diagnosing, monitoring, and assessing treatment effects for A? amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms.

Abstract: The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for A? amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.

Abstract: This invention relates to antibodies to tau and methods of use thereof.

Abstract: The present invention relates to methods of detecting, diagnosing, monitoring, and assessing treatment effects for A? amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms.

Abstract: Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a housing. Devices may be implantable for use in an in vivo active flow system or for use in an in vivo passive system. Devices may also be used in an ex vivo active flow system. Devices may also be used in a passive system to treat cerebrospinal fluid and/or brain interstitial fluid that is withdrawn, or in a passive system that is implanted surgically. Methods include contacting cerebrospinal fluid and/or brain interstitial fluid with a support including at least one protease attached to the support. Proteins contained in the cerebrospinal fluid and/or brain interstitial fluid are cleaved by the protease resulting in the reduction of protein in cerebrospinal fluid and/or brain interstitial fluid.